Rock Creek Group, LP Cue Biopharma, Inc. Transaction History

Rock Creek Group, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$10.06 - $15.3 $359,282 - $546,424	-35,714 Closed	0 $0
Q2 2021 Aug 10, 2021	SELL	$10.9 - $14.53 $155,717 - $207,575	-14,286 Reduced 28.57%	35,714 $416,000
Q1 2021 May 14, 2021	SELL	$11.2 - $16.09 $560,156 - $804,725	-50,014 Reduced 50.01%	50,000 $610,000
Q4 2020 Feb 12, 2021	BUY	$11.12 - $16.4 $222,555 - $328,229	20,014 Added 25.02%	100,014 $1.25 Million
Q3 2020 Oct 30, 2020	BUY	$15.05 - $23.54 $936,110 - $1.46 Million	62,200 Added 349.44%	80,000 $1.2 Million

Q2 2020 Aug 13, 2020	SELL	$12.7 - $30.73 $265,049 - $641,335	-20,870 Reduced 53.97%	17,800 $436,000
Q1 2020 May 15, 2020	BUY	$9.85 - $22.27 $11,524 - $26,055	1,170 Added 3.12%	38,670 $549,000
Q4 2019 Feb 14, 2020	SELL	$7.06 - $17.47 $35,335 - $87,437	-5,005 Reduced 11.78%	37,500 $595,000
Q3 2019 Nov 13, 2019	SELL	$6.78 - $9.28 $48,782 - $66,769	-7,195 Reduced 14.48%	42,505 $358,000
Q2 2019 Aug 14, 2019	BUY	$7.18 - $9.65 $356,846 - $479,605	49,700 New	49,700 $447,000

16.3M

12.9K

39.1K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $34M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Rock Creek Group, LP, based on Form 13F filings with the SEC.

Stay updated on Rock Creek Group, LP with notifications on news.